Farmacia Hospitalaria y Farmacogenómica

Garcia-Alfonso, P; Saiz-Rodriguez, M; Mondejar, R; Salazar, J; Paez, D; Borobia, AM; Safont, MJ; Garcia-Garcia, I; Colomer, R; Garcia-Gonzalez, X; Herrero, MJ; Lopez-Fernandez, LA; Abad-Santos, F.

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

CLINICAL & TRANSLATIONAL ONCOLOGY. 2022; 24(3): 483-494 Nº de citas: 31 [doi:10.1007/s12094-021-02708-4]

Villanueva-Bueno C; Montecatine-Alonso E; Jiménez-Parrilla F; Fernández-Llamazares CM; Manrique-Rodríguez S; Zamora-Flores E; Dolz E; Fernández-Polo A; Catillo-Salinas F; Comuñas J; Gallego-Fernández C; González-López M; Gómez-Trevecedo Calvo MT; Gázquez-Pérez R; Álvarez Del Vayo-Benito C; Gil-Navarro MV.

Antimicrobial defined daily dose in neonatal population.

Enfermedades Infecciosas Y Microbiologia Clinica (english Ed.). 2022; 40(2): 59-65 [doi:10.1016/j.eimce.2021.05.012]

Narrillos-Moraza, A; Gomez-Martinez-Sagrera, P; Amor-Garcia, MA; Escudero-Vilaplana, V; Collado-Borrell, R; Villanueva-Bueno, C; Gomez-Centurion, I; Herranz-Alonso, A; Sanjurjo-Saez, M.

Mobile Apps for Hematological Conditions: Review and Content Analysis Using the Mobile App Rating Scale

JMIR mHealth and uHealth. 2022; 10(2): Nº de citas: 7 [doi:10.2196/32826]

Villanueva-Bueno, C; Montecatine-Alonso, E; Jimenez-Parrilla, F; Fernandez-Llamazares, CM; Manrique-Rodriguez, S; Zamora-Flores, E; Dolz, E; Fernandez-Polo, A; Catillo-Salinas, F; Comunas, J; Gallego-Fernandez, C; Gonzalez-Lopez, M; Calvo, MTGT; Gazquez-Perez, R; del Vayo-Benito, CA; Gil-Navarro, MV; Paediat Antimicrobial Defined Dail.

Antimicrobial defined daily dose in neonatal population

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2022; 40(2): 59-65 Nº de citas: 5 [doi:10.1016/j.eimc.2021.05.007]

Vicente-Valor, J; Garcia-Gonzalez, X; Ibanez-Garcia, S; Duran-Garcia, ME; de Lorenzo-Pinto, A; Rodriguez-Gonzalez, C; Mendez-Fernandez, I; Percovich-Hualpa, JC; Herranz-Alonso, A; Sanjurjo-Saez, M.

PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort

BIOMEDICINE & PHARMACOTHERAPY. 2022; 146: 112519-112519 Nº de citas: 10 [doi:10.1016/j.biopha.2021.112519]

Enriquez-Gomez, A; Ortega-Navarro, C; Fernandez-Cordon, C; Diez-Villanueva, P; Martinez-Selles, M; de Lorenzo-Pinto, A; de Miguel-Yanes, JM.

Comparison of a polypharmacy-based scale with Charlson comorbidity index to predict 6-month mortality in chronic complex patients after an ED visit

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2022; 88(4): 1795-1803 Nº de citas: 2 [doi:10.1111/bcp.15096]

Gil-Manso, S; Blanco, IM; Lopez-Esteban, R; Carbonell, D; Lopez-Fernandez, LA; West, L; Correa-Rocha, R; Pion, M.

Comprehensive Flow Cytometry Profiling of the Immune System in COVID-19 Convalescent Individuals

Frontiers in Immunology. 2022; 12: 793142-793142 Nº de citas: 10 [doi:10.3389/fimmu.2021.793142]

Villanueva-Bueno, C; Escudero-Vilaplana, V; Collado-Borrell, R; Gimenez-Manzorro, A; Ribed, A; Marzal-Alfaro, B; Revuelta-Herrero, JL; Gonzalez-Haba, E; Herranz, A; Sanjurjo, M.

Medication guide for the perioperative management of oral antineoplastic agents in cancer patients

EXPERT OPINION ON DRUG SAFETY. 2022; 21(1): 107-119 Nº de citas: 4 [doi:10.1080/14740338.2021.1965990]

Martinez, CLC; Jimenez, RMR; Vazquez-Lopez, C; Perez-Cordon, L; Hidalgo, SV; Jose, PB.

Recommendations for using oral antineoplastic and immunomodulating agents in oncohematology by enteral tube administration

NUTRICION HOSPITALARIA. 2022; 39(1): 171-201 Nº de citas: 5 [doi:10.20960/nh.03736]

Vicente-Valor, J; Escudero-Vilaplana, V; Collado-Borrell, R; Perez-Ramirez, S; Villanueva-Bueno, C; Narrillos-Moraza, A; Garcia-Sanchez, S; Beamud-Cortes, M; Herranz, A; Sanjurjo, M.

Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. 2022; 17(12): 1467-1473 Nº de citas: 10 [doi:10.1080/17425255.2021.2027908]

Gomez-Centurion, I; Oarbeascoa, G; Garcia, MC; Fresnena, MCL; Carreno, MJM; Vilaplana, VE; Gonzalez-Haba, E; Bailen, R; Dorado, N; Juarez, LM; Macias, GR; Lopez, PF; Encinas, C; Bastos-Oreiro, M; Anguita, J; Sanjurjo, M; Diez-Martin, JL; Kwon, M.

Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility

INTERNATIONAL JOURNAL OF HEMATOLOGY. 2022; 115(1): 61-68 Nº de citas: 11 [doi:10.1007/s12185-021-03219-2]

Soria-Chacartegui, P; Villapalos-Garcia, G; Lopez-Fernandez, LA; Navares-Gomez, M; Mejia-Abril, G; Abad-Santos, F; Zubiaur, P.

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study

Pharmaceutics. 2021; 13(12): Nº de citas: 9 [doi:10.3390/pharmaceutics13122036]

GARCÍA, X.; SALVADOR, S..

Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?

Journal Of Personalized Medicine. 2021; : [doi:https://doi.org/10.3390/jpm11111180]

Morillo Verdugo R; Calvin Lamas M; Delgado Latorre ATJ; Ferrando Piqueres R; Fernández-Llamazares CM; Negro Vega E; Tortajada Goitia B.

Development of the Q-PEX standard for quality certification of pharmaceutical care for outpatients of Pharmacy services

Journal Of Healthcare Quality Research. 2021; 36(6): 324-332 Nº de citas: 6 [doi:10.1016/j.jhqr.2021.03.010]

García-González X; Salvador-Martín S.

Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?

Journal Of Personalized Medicine. 2021; 11(11): Nº de citas: 4 [doi:10.3390/jpm11111180]

Salvador-Martin, S; Melgarejo-Ortuno, A; Lopez-Fernandez, LA.

Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease

Pharmaceutics. 2021; 13(11): Nº de citas: 4 [doi:10.3390/pharmaceutics13111786]

SALVADOR, S.; MELGAREJO, A.; LOPEZ, L..

Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease

Pharmaceutics. 2021; 13(11): [doi:https://doi.org/10.3390/pharmaceutics13111786]

GIL, S.; CARBONELL, D.; LOPEZ, L.; MIGUENS, I.; ALONSO, R.; BUÑO, I.; Muñoz, P.; Ochando Cano, Jordi; PION, M.; CORREA, R..

Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days

Frontiers in Immunology. 2021; 12: 726960-726960 Nº de citas: 18 [doi:10.3389/fimmu.2021.726960]